A Blog from the Lymphoma Program at Weill Cornell Medicine and NewYork-Presbyterian
September 15th is World Lymphoma Awareness Day (#WLAD) a day dedicated to raising awareness of lymphoma. As part of this effort our lymphoma clinicians and researchers participated in the Lymphoma Research Foundation’s #LightitRed campaign to raise lymphoma awareness.
The association between physical activity and a lower risk of non-Hodgkin lymphoma is not well proven and few studies have established any link. However, Cancer Epidemiology, Biomarkers & Prevention published results from a case controlled study on physical activity and the risk of non-Hodgkin lymphoma. In this video Dr. Peter Martin explains the rationale of this case study, its findings, and important takeaways for people who may be at risk for non-Hodgkin lymphoma.
Previous #REDLAMP entries can be viewed on our Youtube channel.
We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 212-746-2919.
The Weill Cornell Lymphoma Program has recently opened a new clinical trial for men and women with refractory MCL, who have failed ibrutinib treatment or were unable to tolerate ibrutinib. The study sponsor is the Bayer Corporation, and the principal investigator at Weill Cornell is Peter Martin M.D.. For more information about the study, please call Amelyn Rodgriguez, RN at (212) 746-1362 or e-mail Amelyn at amr2017@med.cornell.edu.
Key Eligibility
Study Summary
This clinical trial is for men and women with mantle cell lymphoma (MCL) who were previously treated for this disease and who failed ibrutinib treatment or were unable to tolerate ibrutinib treatment.
While treatment of MCL with ibrutinib has yielded promising efficacy, clinicians and researchers are reporting the development of ibrutinib resistance. Clinically, ibrutinib resistance leaves MCL patients without an established recourse for further treatment. Offering a treatment targeting a different pathway provides an opportunity to fulfill an unmet medical need in this patient population. In addition, some patients are unable to tolerate ibrutinib treatment, leaving them without an established therapeutic option after first-line treatment failure.
This is a single-arm, open-label phase 2a study to evaluate the efficacy and safety of copanlisib monotherapy in patients with MCL, who failed ibrutinib treatment or were unable to tolerate ibrutinib. Patients will receive copanlisib IV infusion at a starting dose of 60 mg as single agent on Days 1, 8 and 15 of each 28-day treatment cycle. Patients will continue on treatment as long as they are responding to therapy and not experiencing unacceptable side effects. All patients, except for patients who object to follow-up data collection, will be followed for overall survival at least every 3 months during the survival follow-up period until death or until the end of study, whichever occurs first.
New Developments in Lymphoma 